Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY) will announce the European and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic analysis at a workshop series in four European cities and seven cities in Asia Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.
Roche NimbleGen will provide arrays with the Signature Genomics design in multiplex array formats to accommodate the simultaneous processing and analysis of 3, 6, or 12 samples. The CGX arrays are supported by a comprehensive microarray workflow from Roche that includes NimbleGen reagents and instrumentation. Signature Genomics will offer full support for data analysis using its Genoglyphix® software.
Dr. Lisa G. Shaffer, President and CEO of Signature Genomics and keynote speaker at the workshop events in Europe said, "As one of the pioneers in the field of genomic analysis, we continuously work toward innovation and improvement in the products and services we provide. We feel that the Roche partnership is a synergistic fit between two great organizations. Like us, Roche is focused on technical excellence and delivering valuable and relevant scientific information."
"We, at Roche, are excited to be partnering with Signature Genomics, the market leader in molecular cytogenetic analysis," said Dr. Gerd Maass, CEO of Roche NimbleGen. "This collaboration signifies Roche's incredible progress in the last year towards designing and manufacturing high-quality microarrays with supporting comprehensive workflow solutions that meet the specific needs of researchers in the field of genetic analysis."
For more information about Roche NimbleGen, please access the company's website at: www.nimblegen.com.
About Signature Genomic Laboratories
Signature Genomics, with headquarters in Spokane Washington, is a pioneer in genomic analysis related to human disease. Signature Genomics provides comprehensive genetic analysis and innovative software and support to research organizations and genetic professionals worldwide.
As a leader in the industry, Signature Genomics has established methodologies that are now the standard for microarray analysis. In 2003, the company became the first to provide commercially viable microarray testing and analysis to the healthcare and research services market. With personnel throughout the U.S., Signature Genomics has over 120 employees, including leading scientists and cytogeneticists. As a leader in array based CGH for analysis of chromosomal abnormalities, Signature provides its clients with the assistance and expertise to understand and interpret complex genomic research studies.
The success of Signature Genomics' business resides with its experience, knowledge, service, and support in handling nearly 40,000 individual studies to date. Additionally, the results from these studies have been incorporated into the company's proprietary software, Genoglyphix®, a web- portal that enables researchers to analyze and understand the meaning of genetic alteration and disease.
For more information about Signature Genomics, please access the company's website at www.signaturegenomics.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders
Roche NimbleGen will provide arrays with the Signature Genomics design in multiplex array formats to accommodate the simultaneous processing and analysis of 3, 6, or 12 samples. The CGX arrays are supported by a comprehensive microarray workflow from Roche that includes NimbleGen reagents and instrumentation. Signature Genomics will offer full support for data analysis using its Genoglyphix® software.
Dr. Lisa G. Shaffer, President and CEO of Signature Genomics and keynote speaker at the workshop events in Europe said, "As one of the pioneers in the field of genomic analysis, we continuously work toward innovation and improvement in the products and services we provide. We feel that the Roche partnership is a synergistic fit between two great organizations. Like us, Roche is focused on technical excellence and delivering valuable and relevant scientific information."
"We, at Roche, are excited to be partnering with Signature Genomics, the market leader in molecular cytogenetic analysis," said Dr. Gerd Maass, CEO of Roche NimbleGen. "This collaboration signifies Roche's incredible progress in the last year towards designing and manufacturing high-quality microarrays with supporting comprehensive workflow solutions that meet the specific needs of researchers in the field of genetic analysis."
For more information about Roche NimbleGen, please access the company's website at: www.nimblegen.com.
About Signature Genomic Laboratories
Signature Genomics, with headquarters in Spokane Washington, is a pioneer in genomic analysis related to human disease. Signature Genomics provides comprehensive genetic analysis and innovative software and support to research organizations and genetic professionals worldwide.
As a leader in the industry, Signature Genomics has established methodologies that are now the standard for microarray analysis. In 2003, the company became the first to provide commercially viable microarray testing and analysis to the healthcare and research services market. With personnel throughout the U.S., Signature Genomics has over 120 employees, including leading scientists and cytogeneticists. As a leader in array based CGH for analysis of chromosomal abnormalities, Signature provides its clients with the assistance and expertise to understand and interpret complex genomic research studies.
The success of Signature Genomics' business resides with its experience, knowledge, service, and support in handling nearly 40,000 individual studies to date. Additionally, the results from these studies have been incorporated into the company's proprietary software, Genoglyphix®, a web- portal that enables researchers to analyze and understand the meaning of genetic alteration and disease.
For more information about Signature Genomics, please access the company's website at www.signaturegenomics.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders
